The future of liver transplantation for viral hepatitis

Liver International

Volumn 37, Issue , 2017, Pages 130-135

  Durand, François ^a   Francoz, Claire ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

direct antiviral agents; hepatitis C virus; hepatocellular carcinoma; non alcoholic steatohepatitis

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; COMORBIDITY; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS C; HEPATITIS DELTA VIRUS; HEPATITIS DELTA VIRUS INFECTION; HEPATITIS E; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; RETRANSPLANTATION; REVIEW; TREATMENT INDICATION; VIRUS HEPATITIS; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TUMOR; NONALCOHOLIC FATTY LIVER; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; TRENDS; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS;

EID: 85007524194     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13310     Document Type: Review

References (43)

1. UNOS. United Network for Organ Sharing. 2016. http://www.unos.org/. Accessed 7 December 2016
2. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
3. European Liver Transplant Registry. 2016. www.eltr.org. Accessed 7 December 2016
4. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307–313.
5. Durand F, Renz JF, Alkofer B, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008;14:1694–1707.
6. Agence de la biomédecine. Web Portal. 2016. http://www.sipg.sante.fr/. accessed 7 December 2016
7. Miller CM, Durand F, Heimbach JK, et al. The international liver transplant society guideline on living liver donation. Transplantation. 2016;100:1238–1243.
8. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028–1041.
9. Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013;59:926–933.
10. Perrillo R, Buti M, Durand F, et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013;19:887–895.
11. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–362.
12. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532–543.
13. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844.
14. Ganne-Carrie N, Layese R, Bourcier V, et al. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology. 2016;64:1136–1147.
15. Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2016;16:19698–19712.
16. Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–726.
17. AcsgohcEa. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734–740.
18. Innes H, McDonald S, Hayes P, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2016;54:1547–1558.
19. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
20. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–531.
21. Deuffic-Burban S, Mathurin P, Rosa I, et al. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014;46:157–163.
22. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59:160–168.
23. Cholankeril G, Perumpail RB, Pham EA, et al. Nonalcoholic fatty liver disease: epidemiology, natural history, and diagnostic challenges. Hepatology. 2016;64:954.
24. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of non-alcoholic fatty liver disease (NAFLD) in the United States and Europe. Hepatology. 2016;64:1577–1586.
25. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132–1139 e1.
26. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–1599.
27. Younossi Z, Stepanova M, Saab S, et al. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients. Aliment Pharmacol Ther. 2015;41:209–217.
28. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology. 2000;32:87–90.
29. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 2010;59:1694–1698.
30. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940.
31. Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22:897–905.
32. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–1847.
33. Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117–S131.
34. Uhl P, Helm F, Hofhaus G, et al. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. Eur J Pharm Biopharm. 2016;103:159–166.
35. Kennedy EM, Bassit LC, Mueller H, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196–205.
36. Bordier BB, Marion PL, Ohashi K, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol. 2002;76:10465–10472.
37. Fontana RJ, Engle RE, Scaglione S, et al. The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology. 2016;64:1870–1880.
38. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–817.
39. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111–1120.
40. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494.
41. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823–830.
42. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61:1880–1886.
43. Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence—The ANRS CUPILT study. J Hepatol. 2016;65:711–718.